{"entity":{"id":"sasanlimab","kind":"drug","name":"Sasanlimab","aka":[],"tldr":"Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.","summary":"Sasanlimab (PF-06801591) is a monoclonal antibody developed by Pfizer. Its targets are PD-1 and PD-L1 (the sponsor names PD-1). The sponsor states: A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2. ClinicalTrials.gov describes the intervention as: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04165317 (A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT04165317, plans to enrol 1068 participants (actual) with primary completion was scheduled for 2024-12-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Sasanlimab","url":"https://clinicaltrials.gov/search?intr=Sasanlimab"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["pd1","pdl1"],"drugs":[],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04165317"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PF-06801591","modality":"monoclonal antibody","mechanism":"A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sasanlimab/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"trial":[{"id":"nct04165317","kind":"trial","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","route":"/trials/nct04165317/"}]}}